assignment
Not Recruiting

Phase 2 Open-Label Evaluation of Sacituzumab Govitecan in Patients with Metastatic Solid Tumors

Trial ID
2024-513611-28-00
Protocol
IMMU-132-11

Register record, history and transparency: CTIS.eu

Trial statistics

science
1
test molecule
location_city
8
research sites
public
3
countries
medical_information
1
disease
person_search
12
investigators
handshake
2
vendors

Diseases & Conditions

Neoplasm malignant

Objectives

The primary objective of this study is to assess the **Objective Response Rate (ORR)** of sacituzumab govitecan in subjects with metastatic solid tumors, evaluated by the Investigator's assessment according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria. This is clinically relevant as ORR is a critical measure of a treatment's efficacy, indicating the proportion of patients with a significant reduction in tumor size.

Secondary objectives include:

  • Assessing the ORR, duration of response (DOR), clinical benefit rate (CBR), and progression-free survival (PFS) of sacituzumab govitecan by blinded independent central review (BICR) according to RECIST 1.1 criteria.
  • Evaluating the DOR, CBR, and PFS by Investigator's assessment according to RECIST 1.1 criteria.
  • Assessing the overall survival (OS) of sacituzumab govitecan.
  • Evaluating the safety profile of sacituzumab govitecan.
  • Assessing the pharmacokinetics (PK) and immunogenicity of sacituzumab govitecan.
These secondary objectives provide a comprehensive evaluation of the treatment's efficacy, safety, and biological impact, which are essential for understanding its potential clinical benefits and risks in treating metastatic solid tumors.

Participants

The clinical trial involves a total of **204 participants** diagnosed with **metastatic solid tumors**. The study population includes both male and female subjects, all of whom are over the age of 18. Participants were selected based on their ability to provide informed consent and meet specific health criteria, including an **ECOG Performance Status** score of 0 or 1, adequate hematologic counts, hepatic function, and creatinine clearance. The trial includes individuals with various types of metastatic or locally advanced solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, endometrial carcinoma, and small cell lung cancer, all of which have progressed following prior treatments. Participants are required to have a life expectancy of at least three months and measurable disease as per RECIST 1.1 criteria. Both genders are represented, and the trial includes a vulnerable population. Lifestyle factors such as diet and physical activity are not specified, but participants must adhere to protocol-specified contraception methods if applicable.

Plans and Procedures

The clinical trial is designed to evaluate the **objective response rate (ORR)** of **sacituzumab govitecan** in subjects with **metastatic solid tumors**. This is a Phase 2, open-label study, which means that both the researchers and participants know the treatment being administered. The trial aims to assess the efficacy of the investigational drug by the Investigator's assessment according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria. The study is expected to conclude by March 31, 2025, with recruitment having started on September 30, 2022.

Participants will undergo a series of study visits, beginning with a screening visit to determine eligibility based on specific inclusion criteria, such as age, ability to provide informed consent, and having histologically documented metastatic or locally advanced solid tumors. The screening process will also involve the submission of tumor specimens and assessment of **ECOG Performance Status**. Following successful screening, participants will receive the investigational drug, **Trodelvy**, administered as a solution for infusion via intravenous use.

Throughout the trial, participants will attend follow-up visits to monitor treatment response and safety. These visits will include assessments of **hematologic counts**, hepatic function, and **creatinine clearance**. The primary endpoint is the ORR, while secondary endpoints include duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and the incidence of treatment-emergent adverse events (AEs). The study will also measure serum concentrations of sacituzumab govitecan and the incidence of anti-drug antibodies (ADA).

The expected length of participant involvement is contingent upon the individual's response to treatment and overall health status. Conditions that may lead to early termination from the study include significant adverse events, disease progression, or withdrawal of consent. Participants must have a life expectancy of at least three months and agree to use specified methods of contraception if applicable. The trial is not categorized as low intervention and is conducted in accordance with regulatory standards.

Treatment

The clinical trial involves the administration of **Trodelvy**, a pharmaceutical product containing the active substance **sacituzumab govitecan**. Trodelvy is formulated as a **powder for concentrate for solution for infusion** and is intended for **intravenous use**. The product is supplied in a dosage strength of 200 mg per vial. The administration schedule involves reconstituting the powder to prepare a solution for infusion, which is then administered intravenously. The dosing regimen is determined based on the participant's body weight, with the dose expressed in milligrams per kilogram (mg/kg). The maximum daily dose and total dose amounts are not specified, indicating that dosing is adjusted according to individual patient needs and clinical judgment. The treatment period is defined as a maximum of one cycle, with the specific duration of each cycle not detailed in the provided data.

In this study, Trodelvy is the experimental medication being evaluated for its efficacy in subjects with metastatic solid tumors. The primary objective is to assess the overall response rate (ORR) of sacituzumab govitecan, as determined by the Investigator's assessment according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria. No non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, are mentioned in the provided data. Participant compliance with the dosing regimen is monitored throughout the study to ensure adherence to the protocol and to evaluate the safety and efficacy of the treatment. The trial is conducted under the sponsorship of Gilead Sciences Ireland Unlimited Company, and the product is authorized for use in the European Union.

Efficacy

Efficacy in the clinical trial will be assessed primarily through the **Objective Response Rate (ORR)**, as determined by the Investigator's assessment according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). Secondary endpoints include ORR, Duration of Response (DOR), Clinical Benefit Rate (CBR), and Progression-Free Survival (PFS) as evaluated by both the Investigator and an independent Blinded Independent Central Review (BICR). Additionally, Overall Survival (OS) and the incidence of treatment-emergent adverse events (AEs) and clinical laboratory abnormalities will be monitored. Serum concentrations of sacituzumab govitecan and the incidence of anti-drug antibody (ADA) to sacituzumab govitecan will also be measured over time.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Subjects meeting all the following inclusion criteria at Screening will be eligible for participation in the study. Female or male subjects, > 18 years of age, who are able to understand and give written informed consent.
  • Subjects with the following histologically documented metastatic (M1, Stage IV) or locally advanced solid tumors. 2.1 NSCLC (adenocarcinoma or SCC) that has progressed after prior platinum-based chemotherapy and programmed death-(ligand) 1 (PD- (L)1) directed therapy given sequentially (in either order) or in combination. These agents could have been taken as monotherapy or in combination with other agents. If subjects have had recurrence/relapse or lack of response within 6 months of completing chemotherapy with or without PD-(L)1 directed therapy for locally advanced disease, that line of therapy may be counted for eligibility. 2.2 HNSCC that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy given sequentially (in either order) or in combination. These agents could have been taken as monotherapy or in combination with other agents. No more than 3 prior lines of systemic treatment is allowed. 2.3 Endometrial carcinoma that has progressed after prior platinum-based chemotherapy and anti- PD-(L)1 directed therapy given sequentially (in either order) or in combination. These agents could have been taken as monotherapy or in combination with other agents. No more than 3 prior lines of systemic treatment is allowed. Endometrial carcinoma with any histology including microsatellite instability-high /mismatch repair deficient and microsatellite stable (MSI-h/dMMR and MSS) are allowed. 2.4 Extensive stage SCLC that has progressed after prior platinum-based chemotherapy and PD-(L)1 directed therapy. No more than one prior line of systemic treatment is allowed (re-challenge with the same initial regimen is not allowed).
  • ECOG Performance Status score of 0 or 1.
  • Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500/mm3, and platelets ≥ 100,000/μL).
  • Adequate hepatic function (bilirubin ≤ 1.5 institutional upper limit of normal [IULN], aspartate aminotransferase [AST], and alanine aminotransferase [ALT] ≤ 2.5 × IULN or ≤ 5 × IULN if known liver metastases and serum albumin > 3 g/dL).
  • Creatinine clearance ≥ 30 mL/min as assessed by Cockcroft-Gault.
  • Subjects must have at least a 3-month life expectancy.
  • Have measurable disease by CT or MRI scan as per RECIST 1.1 criteria. Tumor lesions situated in a previously irradiated area may be utilized if they are considered measurable and PD has been demonstrated in such lesions
  • Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
  • Tumor blocks (preferably obtained within 12 months of study entry if clinically feasible) or 20 newly sectioned unstained slides (6 slides minimum) of archived biopsy/surgical specimens are requested. A baseline biopsy is required if archival tissue is not available. Fine needle aspirates and bone biopsies are not suitable samples. These specimens should be submitted within the 28-day screening period, after the subject provides written informed consent.
cancel

Exclusion Criteria

  • Subjects meeting any of the following exclusion criteria at Screening will not be enrolled in the study. Positive serum pregnancy test (Appendix 17.5) or women who are lactating.
  • Are currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to the first dose of study drug. Subjects participating in observational studies are eligible.
  • Have had a prior anti-cancer biologic agent within 4 weeks prior to study Day 1 or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1.
  • Have not recovered (ie, ≤ Grade 1) from AEs due to a previously administered agent.
  • Have previously received topoisomerase I inhibitors (for SCLC cohort: Etoposide with platinum combination in first-line setting is allowed).
  • Have an active second malignancy.
  • Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, no evidence of new or enlarging brain metastases and are taking ≤ 20 mg/day of prednisone or its equivalent. All subjects with carcinomatous meningitis are excluded regardless of clinical stability.
  • Have active cardiac disease, defined as: 8.1 Myocardial infarction or unstable angina pectoris within 6 months of Day 1. 8.2 History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication); history of QT interval prolongation. 8.3 New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%.
  • Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease), immune-mediated colitis, or gastrointestinal (GI) perforation within 6 months of C1D1.
  • Have an active infection requiring IV antibiotics.
  • Have positive human immunodeficiency virus (HIV)-1 or HIV-2 antibody with detectable viral load or taking medications that may interfere with SN-38 (the active metabolite of sacituzumab govitecan).
  • Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), subjects with a detectable viral load will be excluded. 12.1 Subjects who test positive for hepatitis B surface antigen (HBsAg). Subjects who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. 12.2 Subjects who test positive for HCV antibody. Subjects who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Subjects with a known history of HCV or a positive HCV antibody test will not require an HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
  • Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  • Impending need for palliative radiation therapy or surgery for pathological fractures and/or for medullary compression within 4 weeks prior to initiating study treatment
  • Additional cohort-specific exclusion criteria:- NSCLC cohort (adenocarcinoma and SCC): 15.1 Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of enrollment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc); any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc); or prior pneumonectomy. - HNSCC cohort: 15.2 Subjects with nasopharynx carcinoma. 15.3 Subjects who had progressive disease within 6 months of completion of curative therapy. - Endometrial carcinoma cohort: 15.4 Subjects who have carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma, and/or endometrial stromal sarcomas. - Small cell lung cancer cohort: 15.5 Subjects who never received platinum-containing regimen for SCLC. 15.6 Limited-stage subjects who are candidates for local or regional therapy.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Belgium BelgiumNot Recruiting30 Sept 20222
France FranceNot Recruiting30 Sept 202212
Spain SpainNot Recruiting30 Sept 20229

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Trodelvy 200 mg powder for concentrate for solution for infusion
TestPOWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS USE001PRD9351384

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Sacituzumab Govitecan
35 trials

Also investigated for

Triple negative breast cancer 10Bladder cancer 4Breast cancer female 4Non-small cell lung cancer 4